Haemolytic disease of the fetus and newborn

Haemolytic Disease of the Fetus and Newborn (HDFN) is caused by maternal alloimmunization against red blood cell antigens. In severe cases, HDFN may lead to fetal anaemia with a risk for fetal death and to severe forms of neonatal hyperbilirubinaemia with a risk for kernicterus. Most severe cases ar...

Full description

Saved in:
Bibliographic Details
Published in:Vox sanguinis 2015-08, Vol.109 (2), p.99-113
Main Authors: de Haas, M., Thurik, F. F., Koelewijn, J.M., van der Schoot, C.E.
Format: Article
Language:English
Subjects:
alloimmunisation in pregnancy
anti-D prophylaxis
Antigens
Blood diseases
Erythroblastosis, Fetal - diagnosis
Erythroblastosis, Fetal - immunology
Erythroblastosis, Fetal - therapy
Female
fetal genotyping
Fetuses
haemolytic disease of the fetus and newborn
Hematology
Humans
Immunoglobulins
Immunotherapy
Infant, Newborn
Newborn babies
Pregnancy
RBC antigens and antibodies
Rh-Hr Blood-Group System - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Haemolytic Disease of the Fetus and Newborn (HDFN) is caused by maternal alloimmunization against red blood cell antigens. In severe cases, HDFN may lead to fetal anaemia with a risk for fetal death and to severe forms of neonatal hyperbilirubinaemia with a risk for kernicterus. Most severe cases are caused by anti‐D, despite the introduction of antental and postnatal anti‐D immunoglobulin prophylaxis. In general, red blood cell antibody screening programmes are aimed to detect maternal alloimmunization early in pregnancy to facilitate the identification of high‐risk cases to timely start antenatal and postnatal treatment. In this review, an overview of the clinical relevance of red cell alloantibodies in relation to occurrence of HDFN and recent views on prevention, screening and treatment options of HDFN are provided.
ISSN:0042-9007
1423-0410
DOI:10.1111/vox.12265